<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026441</url>
  </required_header>
  <id_info>
    <org_study_id>Vela100</org_study_id>
    <nct_id>NCT01026441</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Safety and Efficacy of the Vela100</brief_title>
  <official_title>Clinical Study to Evaluate the Safety and Efficacy of the Vela100/eShape Uno Device for Cellulite and Circumference Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Medical</source>
  <brief_summary>
    <textblock>
      This study is intended to test the safety of the Vela100 device when used for treatment for&#xD;
      cellulite and circumference temporary reduction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Product was not developed and study was cancelled&#xD;
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>End of treatment, at 1 month FU</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cellulite Reduction</condition>
  <condition>Circumference Reduction</condition>
  <arm_group>
    <arm_group_label>Treatment for cellulite and circumference reduction</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will be treated with the device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vela100 (Aesthetic)</intervention_name>
    <description>6 treatments once a week</description>
    <arm_group_label>Treatment for cellulite and circumference reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent agreement signed by the subject.&#xD;
&#xD;
          -  Healthy males or females older than 21 years of age but not older than 60 years of&#xD;
             age.&#xD;
&#xD;
          -  Fitzpatrick Skin Type I to VI&#xD;
&#xD;
          -  Having at least two areas (abdomen, buttocks and thighs) suitable for treatment.&#xD;
&#xD;
          -  BMI score is greater than 18.5 and less than 29.9 - normal to overweight, but not&#xD;
             obese.&#xD;
&#xD;
          -  Willingness to follow the treatment and follow-up schedule and the post-treatment&#xD;
             care.&#xD;
&#xD;
          -  Willingness to refrain from a change in diet/drinking/exercise/medication regimen for&#xD;
             the entire course of the study.&#xD;
&#xD;
          -  For female of child bearing potential - using a medically acceptable form of birth&#xD;
             control at least 3 months prior to enrollment and during the entire course of the&#xD;
             study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with&#xD;
             spermicide, or abstinence).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or planning to become pregnant, having given birth (vaginal birth or&#xD;
             Caesarean surgery) less than 9 months ago, and/or breastfeeding.&#xD;
&#xD;
          -  Having any active electrical implant anywhere in the body, such as a pacemaker or an&#xD;
             internal defibrillator.&#xD;
&#xD;
          -  Having a permanent implant in the treated areas, such as metal plates and screws or an&#xD;
             injected chemical substance.&#xD;
&#xD;
          -  Having received treatment with laser, RF or other devices in the treated areas within&#xD;
             6 months of treatment or during the study.&#xD;
&#xD;
          -  Having undergone a liposuction surgery or any contouring treatment in the areas&#xD;
             intended for treatment within 9 months of treatment or during the study.&#xD;
&#xD;
          -  For post-liposuction areas, the procedure should also not have been performed more&#xD;
             than 2 years prior to this study.&#xD;
&#xD;
          -  Having undergone any other surgery in the treated areas within 9 months of treatment&#xD;
             or during the study.&#xD;
&#xD;
          -  Having or undergoing any form of treatment for active cancer, or having a history of&#xD;
             skin cancer or any other cancer in the areas to be treated, including presence of&#xD;
             malignant or pre-malignant pigmented lesions.&#xD;
&#xD;
          -  Suffering from significant concurrent illness, such as cardiac disorders, diabetes&#xD;
             (type I or II), lupus, porphyria, or pertinent neurological disorders.&#xD;
&#xD;
          -  Having a known anticoagulative or thromboembolic condition or taking anticoagulation&#xD;
             medications one week prior to and during the treatment course (to allow inclusion,&#xD;
             temporary cessation of use as per the subject's physician discretion).&#xD;
&#xD;
          -  History of immunosuppression/immune deficiency disorders (including HIV infection or&#xD;
             AIDS) or currently using immunosuppressive medications.&#xD;
&#xD;
          -  Suffering from hormonal imbalance which may affect weight or cellulite, as per the&#xD;
             Investigator's discretion.&#xD;
&#xD;
          -  History of significant lymphatic drainage problems. Suffering from significant skin&#xD;
             conditions in the treated areas or inflammatory skin conditions, including, but not&#xD;
             limited to, open lacerations or abrasions and active cold sores or herpes sores prior&#xD;
             to treatment (duration of resolution as per the Investigator's discretion) or during&#xD;
             the treatment course.&#xD;
&#xD;
          -  History of keloid scarring or of abnormal wound healing.&#xD;
&#xD;
          -  History of being especially prone to bruising.&#xD;
&#xD;
          -  History of epidermal or dermal disorders (particularly if involving collagen or&#xD;
             microvascularity).&#xD;
&#xD;
          -  Use of isotretinoin (AccutaneÂ®) within 6 months of treatment or during the study.&#xD;
&#xD;
          -  Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing&#xD;
             agents) during, as well as two weeks before and after, the treatment course.&#xD;
&#xD;
          -  Use of anti-cellulite creams within a month of treatment or during the course of the&#xD;
             study.&#xD;
&#xD;
          -  If any allergy that is related to the lotion used in this study appears, subjects may&#xD;
             be excluded from the study.&#xD;
&#xD;
          -  Recently tanned in areas to be treated and/or unable or unlikely to refrain from&#xD;
             tanning during the study.&#xD;
&#xD;
          -  Significant change in diet or exercise regimen within a month of enrollment or during&#xD;
             this study and/or weight loss or gain of 10 lbs (4.5 kgs) within 2 months of&#xD;
             enrollment or during this study.&#xD;
&#xD;
          -  Participation in a study of another device or drug within 1 month prior to enrollment&#xD;
             or during this study.&#xD;
&#xD;
          -  As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orange Coast Women's Medical Group</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kavali Plastic Surgery and Skin Renewal Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>VP Research and Development</name_title>
    <organization>Syneron</organization>
  </responsible_party>
  <keyword>Aesthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

